Boston Scientific Corporation (BSX) Stake Increased by Janus Henderson Group PLC

Tributary Capital Management Llc decreased Boston Scientific Corp Com (BSX) stake by 68.95% reported in 2017Q2 SEC filing. The firm owned 292,474 shares of the medical equipment provider's stock after purchasing an additional 6,495 shares during the quarter. Finally, Peddock Capital Advisors LLC bought a new position in Boston Scientific Corporation during the 2nd quarter valued at $201,000. It increased, as 41 investors sold BSX shares while 173 reduced holdings. The company had a trading volume of 3,383,917 shares. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider's stock worth $131,000 after buying an additional 49 shares during the period. Comerica Securities Inc. increased its holdings in shares of Boston Scientific Corporation by 0.9% during the 2nd quarter. Toronto Dominion Bank now owns 463,826 shares of the medical equipment provider's stock valued at $12,854,000 after purchasing an additional 95,902 shares during the period. Quadrant Capital Group LLC boosted its position in Boston Scientific by 10.3% in the first quarter. Cleararc Capital Inc. now owns 33,322 shares of the medical equipment provider's stock worth $829,000 after purchasing an additional 251 shares during the period. They now have a $34.00 price target on the medical equipment provider's stock. The institutional investor held 579,918 shares of the medical and dental instruments company at the end of 2017Q2, valued at $16.08M, down from 715,558 at the end of the previous reported quarter. Verity Asset holds 0.18% in Boston Scientific Corporation (NYSE:BSX) or 8,424 shares. Through this figure traders can analyze that BSX show whether or not a stock now most active and standing in buying side or sell side. The company maintains price to book ratio of 0.00 industry average at 0.56. The firm has a 50-day moving average of $28.71 and a 200-day moving average of $27.19.

Boston Scientific Corporation (NYSE:BSX), stock is trading $29.54 above the 52-week high and has displayed a high EPS growth of -2.80% in last 5 years.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on October, 25. The medical equipment provider reported $0.29 EPS for the quarter, missing the Zacks' consensus estimate of $0.30 by $0.01. Boston Scientific had a return on equity of 23.70% and a net margin of 4.14%. The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Its sales stood at 44.90% a year on average in the period of last five years. The firm's revenue was up 6.2% compared to the same quarter past year. Boston Scientific Corporation had 63 analyst reports since July 27, 2015 according to SRatingsIntel. (MGNX) price hitting a mean target of $30 a share, meaning the stock still has potential that could lift the price another 71.23% Also, the recent close suggests the stock is underpriced by 151.14% compared to the most bullish target. Following the completion of the sale, the executive vice president now directly owns 174,681 shares in the company, valued at approximately $5,107,672.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP John Bradley Sorenson sold 2,100 shares of the firm's stock in a transaction on Monday, July 31st. The stock was sold at an average price of $29.12, for a total transaction of $10,108,629.44. The disclosure for this sale can be found here.

BTIG Research maintained the shares of BSX in report on Sunday, September 6 with "Buy" rating. Jefferies Group LLC restated a "hold" rating and set a $26.00 price target on shares of Boston Scientific in a report on Friday, February 3rd. The stock of Boston Scientific Corporation (NYSE:BSX) has "Buy" rating given on Wednesday, June 28 by Barclays Capital. That's a potential 4.76 increase relative to where Boston Scientific Corporation (NYSE:BSX) has been trading recently. Zacks Investment Research cut Boston Scientific from a "hold" rating to a "sell" rating in a report on Wednesday, April 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. The company now has a consensus rating of "Buy" and a consensus target price of $30.13.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Equities Focus and is the property of of Equities Focus. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of USA & worldwide copyright & trademark legislation. The legal version of this piece can be viewed at

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX?

Like this


15 October 2017
China's runaway space station is headed for a crash landing into Earth
Tiangong-1, which means heavenly palace in English, comprises of single-module with only one docking port for Shenzhou spacecraft. It was used for both manned and unmanned missions and visited by China's first female astronaut, Liu Yang, in 2012.

15 October 2017
'Happy Death Day' crushes 'Blade Runner 2049' with US$26.5 million
Universal backed the low-budget picture, with Jason Blum's Blumhouse producing. "Blumhouse is just having a tremendous year", said Orr.

15 October 2017
Janus Henderson Group PLC Acquires 15075946 Shares of Sensata Technologies Holding NV
Finally, Cowen and Company started coverage on shares of Sensata Technologies Holding in a report on Tuesday, March 21st. Tredje AP fonden increased its position in shares of Sensata Technologies Holding 174.7% during the 2nd quarter.

15 October 2017
Maverick Capital Ltd. Buys 14280 Shares of HCA Holdings, Inc. (HCA)
The company reported $1.75 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.80 by ($0.05). Meeder Asset Mngmt Incorporated invested 0.36% in HCA Healthcare Inc (NYSE:HCA). 30,513 are owned by Meritage Portfolio Mgmt.

15 October 2017
Santa Cruz and Mares Win Big, Setting Up Another Showdown
Gutierrez fell to 35-2 with one draw after two judges scored the fight 99-91 for Mares and the other had it a flawless 100-90. A high octane opening round for Santa Cruz was punctuated with a pair of right hands that briefly shook his challenger.

15 October 2017
Oppenheimer Holdings, Inc. Reiterates "Buy" Rating for Bank of America Corporation (BAC)
It is negative, as 84 investors sold CVS shares while 559 reduced holdings. 76 funds opened positions while 139 raised stakes. Following the transaction, the director now owns 50,000 shares of the company's stock, valued at approximately $1,208,000.

15 October 2017
Liberty Global plc (LBTYK) stock price up 0.52%
The institutional investor owned 57,581 shares of the company's stock after buying an additional 35,502 shares during the quarter. Finally, Zacks Investment Research cut Liberty Global PLC from a "buy" rating to a "hold" rating in a research note on Tuesday.

15 October 2017
24 passengers on-board Goa-Mumbai Tejas Express suffer food poisoning, hospitalised
The high-end Tejas Express was launched recently and it runs between Mumbai and Goa as a premium train of the Indian Railways. Around 12pm, 3 passengers complained that they were feeling uneasy and felt like vomiting.

15 October 2017
Amber Alert issued for 16-year-old abducted in Woodbridge
Police said she was wearing a white, long-sleeve shirt with a purple stripe, denim jeans and a light-colored jacket. Prince William County police said Sinahi and Segovia were at a party when they got into a fight and got separated.

15 October 2017
UK, Germany reiterate commitment to Iran nuclear deal
AIPAC is one of the most influential lobbying groups in America, helping advance Israel-American policy decisions in Congress. The deal was also created to halt Iranian nuclear proliferation for 10 to 15 years.